• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.

    5/12/26 4:15:27 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PAVS alert in real time by email
    6-K 1 pavs_6k.htm FORM 6-K pavs_6k.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of May 2026

     

    PARANOVUS ENTERTAINMENT TECHNOLOGY LTD.

    (Exact name of registrant as specified in its charter)

     

    250 Park Avenue, 7th Floor

    New York, NY 10017

    (Address of Principal Executive Office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F  ☒      Form 40-F  ☐

     

     

     

     

    Enter into a Material Contract

     

    On May 7, 2026, Paranovus Entertainment Technology Ltd. (the “Company”) purchased a secured convertible promissory note (the “Note”) from Knox Golf Academy, Inc., a company incorporated under the laws of New York (“Knox”), in the aggregate principal amount of up to US$1,000,000 (the “Principal Amount”). The Note will be funded in two tranches of US$500,000 each. The first tranche of US$500,000 was funded upon the issuance of the Note, and the funding of the second tranche of US$500,000 shall be at the sole discretion of the Company, subject to the terms and conditions set forth in the Note. The outstanding Principal Amount will have interest at a rate of ten percent (10%) per annum.

     

    The Note has a term of twelve (12) months from the date of the first disbursement, and is convertible into shares of common stock of Knox at the election of the Company based on a conversion formula that references the ratio of the Principal Amount to certain qualifying golf course renovation costs incurred by Knox, subject to a maximum renovation cost amount of $10.0 million. The Note is secured by substantially all assets of Knox and a pledge of all outstanding equity interests of the Knox pursuant to customary security documents. In addition, the obligations under the Note are guaranteed by the Knox’s controlling shareholder, who owns approximately 80% of Knox’s equity interests. The Note also contains customary representations, warranties, covenants and events of default.

     

    In addition, the Company has the right to appoint one director to the board of directors of Knox.

     

    The foregoing description of the Note does not purport to be complete and is qualified in its entirety by reference to the full text of the form of Note, a copy of which is attached hereto as Exhibit 10.1, and incorporated herein by reference.

     

     
    2

     

     

    EXHIBIT INDEX

     

    Exhibit No.

     

    Description

    10.1

     

    Form of the Secured Convertible Promissory Note of Knox Golf Academy. Inc., dated May 7, 2026

     

     
    3

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

    Paranovus Entertainment Technology Ltd.

     

     

     

     

     

    Date: May 12, 2026

    By:

    /s/ Xiaoyue Zhang

     

     

     

    Xiaoyue Zhang

    Chief Executive Officer

     

     

     
    4

     

    Get the next $PAVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PAVS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PAVS
    SEC Filings

    View All

    SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.

    6-K - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    6/16/26 4:15:23 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 424B5 filed by Paranovus Entertainment Technology Ltd.

    424B5 - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    6/16/26 12:45:38 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.

    6-K - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    6/15/26 10:10:10 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PAVS Announces Pricing of a $10 Million Registered Direct Offering of Class A Ordinary Shares and Pre-Funded Warrants

    NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- PAVS (NASDAQ:PAVS) (the "Company"), a consumer products and digital commerce solutions company, today announced that it has entered into a definitive agreement with certain institutional investors for a registered direct offering of an aggregate of 50,000,000 Class A ordinary shares (or pre-funded warrants to purchase Class A ordinary shares in lieu thereof) at a purchase price of $0.20 per share. The gross proceeds to the Company from the offering are expected to be approximately $10 million, before deducting offering expenses. The offering is expected to close on or about June 16, 2026, subject to the satisfaction of customary closing conditio

    6/15/26 2:30:00 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Beyond Fast Fashion: Advanced Fibers and Smart Manufacturing Are Reshaping the Global Textile Industry

    DENVER, June 15, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – The textile and apparel sector is rarely considered one of the market's most exciting industries. Yet some of today's most intriguing innovation stories are emerging from companies seeking to transform how fabrics are produced, sourced, and utilized across global supply chains. From recombinant spider silk to direct-to-consumer activewear brands and expanding manufacturing capacity, a new generation of companies is positioning itself around themes that include sustainability, performance materials, advanced manufacturing, and next-generation consumer products. Investors searching for emerging opportunities are increasingl

    6/15/26 10:36:44 AM ET
    $GIII
    $JRSH
    $PAVS
    Apparel
    Consumer Discretionary
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Announces Pricing of $5 Million Registered Direct Offering At-The-Market Under NASDAQ Rules

    NEW YORK, March 24, 2026 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS) today announced that it has entered into a definitive agreement with a single institutional investor for a registered direct offering priced at-the-market under Nasdaq Rules of an aggregate of 14,285,715 Class A ordinary shares (or Class A ordinary share equivalents in lieu thereof) at a purchase price of $0.35 per share. The gross proceeds to the Company from the offering are expected to be approximately $5 million, before deducting placement agent commissions and other offering expenses. The offering is expected to close on or about March 25, 2026, subject to the satisfaction of customary clos

    3/24/26 3:09:00 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Xu Minzhu

    3 - Paranovus Entertainment Technology Ltd. (0001751876) (Issuer)

    4/6/26 2:07:10 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Xu George Yijian

    3 - Paranovus Entertainment Technology Ltd. (0001751876) (Issuer)

    3/20/26 2:23:50 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Guo Ling

    3 - Paranovus Entertainment Technology Ltd. (0001751876) (Issuer)

    3/20/26 2:23:24 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:56:47 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:56:31 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:55:36 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Financials

    Live finance-specific insights

    View All

    Paranovus Entertainment Technology Limited Regains Compliance with Nasdaq Minimum Bid Price Requirement

    NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS) today announced that on January 6, 2026, it received notification from the Nasdaq Office of General Counsel stating that the Company had regained compliance with the bid price requirement as set forth in Listing Rule 5550(a)(2) and that Company is therefore in compliance with the Nasdaq Capital Market's listing requirements. As a result, the scheduled hearing before the Hearings Panel on January 29, 2026 had been cancelled and the matter was closed. The Company's Class A ordinary shares will continue to be listed and traded on The Nasdaq Capital Market under the ticker "PAVS."

    1/9/26 8:45:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Received Nasdaq Delisting Notice

    NEW YORK, Dec. 22, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS), announced today that the Company received a letter from the Nasdaq Stock Market LLC ("Nasdaq") on December 17, 2025, notifying the Company that the Nasdaq staff has determined to delist the Company's Class A ordinary shares from The Nasdaq Capital Market, because the Company failed to comply with the Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the "Rule"). As previously disclosed, on July 11, 2025, the Nasdaq staff notified the Company that the bid price of its listed Class A ordinary

    12/22/25 4:30:00 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Announces 1-For-100 Reverse Share Split

    NEW YORK, Dec. 16, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS), today announced that it will effect a reverse share split of its outstanding Class A ordinary shares, par value $0.01 per share (the "Class A Ordinary Shares"), at a ratio of 1-for-100, to be effective at the open of business on Thursday, December 18, 2025. Our Class A Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market ("Nasdaq") on Thursday, December 18, 2025. Following the reverse share split, the Class A Ordina

    12/16/25 9:00:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care